Does Anthem (Elevance Health) Cover Repatha (Evolocumab)?

What Repatha Is and Why Coverage Gets Complicated

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. FDA approval for evolocumab covers three indications: adults with heterozygous familial hypercholesterolemia (HeFH), adults or pediatric patients aged 13 and older with homozygous familial hypercholesterolemia (HoFH), and adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The drug works differently from statins. Statins reduce cholesterol synthesis; evolocumab blocks the destruction of LDL receptors, allowing the liver to clear more LDL from circulation. That mechanism produces substantial LDL reductions. In the FOURIER trial (N=27,564), adding evolocumab 140 mg every two weeks to background statin therapy reduced LDL-C by 59% from a median baseline of 92 mg/dL, and reduced the composite cardiovascular endpoint of MI, stroke, or cardiovascular death by 15% versus placebo over a median follow-up of 2.2 years (HR 0.85 to 95% CI 0.79, 0.92, P<0.001) [2].

Because evolocumab costs approximately $580/month at list price, insurers including Anthem place it on specialty tiers and apply coverage management tools like prior authorization and step therapy. These are not arbitrary barriers. They reflect both the cost of the drug and the clinical reality that most patients with elevated LDL have not yet maximized cheaper options [3].

Coverage rules vary across Anthem's many plan types. A large-group commercial PPO in Ohio may apply different step-therapy requirements than a Medicaid managed-care plan in California under the Elevance Health umbrella. Always verify your specific plan's current formulary at anthem.com or by calling the member services number on your insurance card.

How Anthem's Prior Authorization Criteria Work for Repatha

Prior authorization for Repatha on Anthem commercial plans requires documented evidence of medical necessity before the pharmacy or specialty pharmacy will dispense the drug at the covered rate. Most Anthem PA criteria for evolocumab include all of the following requirements, though exact language changes periodically [4].

First, the patient must carry a documented diagnosis of HeFH, HoFH, or established ASCVD. For ASCVD, this typically means a prior MI, prior ischemic stroke, or symptomatic peripheral artery disease confirmed in chart notes. A high Framingham risk score alone is usually insufficient [5].

Second, the prescribing physician must document that the patient has been on maximally tolerated statin therapy. For most plans, "maximally tolerated" means the highest dose the patient can take without intolerable adverse effects, with documentation of any dose-limiting side effects. Anthem frequently requires this to mean a high-intensity statin such as atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg per the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol [6].

Third, many Anthem plans require a trial of ezetimibe 10 mg daily in addition to the statin, with documented failure to reach LDL-C goal or documented intolerance to ezetimibe [6].

Fourth, the prescriber must provide a recent LDL-C lab value, typically within the past 90 days, showing the patient remains above the guideline-recommended threshold despite optimized oral therapy.

The PA submission goes through Anthem's pharmacy benefit management system, which in many regions is IngenioRx (Anthem's own PBM) or Caremark (CVS). Your prescriber's office must submit a complete PA package: chart notes, lab values, and a letter of medical necessity. Incomplete submissions are the single most common reason for initial denial [7].

The HealthRX PA Readiness Checklist for Evolocumab

Before your prescriber submits the PA, confirm you have all of the following:

1. Diagnosis documentation: ICD-10 code for HeFH (E78.01), HoFH (E78.02), or ASCVD (e.g., I25.10 for chronic ischemic heart disease)
2. LDL-C lab result dated within 90 days showing value above goal on current therapy
3. 90-day medication history showing high-intensity statin at maximum tolerated dose
4. Documentation of ezetimibe trial (date started, date stopped or current use, reason for stopping if applicable)
5. Letter of medical necessity from a board-certified cardiologist or lipidologist where possible
6. Notes documenting any statin intolerance, including which statins were tried and at what doses

A PA submission that includes all six items at the first attempt reduces the rate of initial denial substantially compared with partial submissions, based on HealthRX's review of member case histories.

Step Therapy: What You Must Try Before Repatha

Step therapy means the insurer requires a patient to try and fail one or more less expensive alternatives before the specialty drug is approved. Anthem's step therapy for evolocumab is generally two steps [8].

Step 1. A high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 8 to 12 weeks. Documentation of ongoing statin use or a history of intolerance with specific notation of which drug caused what symptom is required.

Step 2. Ezetimibe 10 mg daily added to the statin for at least 8 to 12 weeks, or documentation of ezetimibe intolerance [9].

Patients with HoFH may have an abbreviated step-therapy requirement because high-intensity statins produce limited LDL reduction in that population due to absent or severely reduced LDL receptor activity. Prescribers treating HoFH should note this explicitly in the PA letter, referencing the American Heart Association's scientific statement on HoFH [10].

Statin intolerance is a documented reason to skip or shorten step therapy. Anthem typically requires documentation of two separate statin trials at the lowest available dose with objective symptoms (myalgia with CK elevation, hepatotoxicity, or confirmed rhabdomyolysis) before accepting intolerance as sufficient to bypass Step 1. Subjective muscle ache without objective findings is often not accepted without additional support [11].

The SAMSON trial (N=200, BMJ 2020) found that nocebo effects account for a significant portion of reported statin intolerance: participants who could not tolerate open-label statin completed 90% of blinded statin months versus 70% of blinded placebo months, with the majority of symptoms attributed to expectation rather than pharmacology [12]. Anthem's medical reviewers are aware of this data. Prescribers arguing against step therapy based on intolerance should provide objective findings where available.

Formulary Tier and Out-of-Pocket Cost on Anthem Plans

Repatha sits on the specialty drug tier of Anthem formularies, which is Tier 4 or Tier 5 on most commercial plan designs. Specialty tier cost-sharing is typically a percentage coinsurance rather than a flat copay, often 25% to 33% of the negotiated drug cost after deductible [13].

At a negotiated price of roughly $500 to $580/month, that coinsurance translates to $125 to $190/month for a member who has met their deductible. Before meeting the deductible, the full negotiated cost applies. For members on high-deductible health plans (HDHPs) with a deductible of $3,000 or more, the first several months of the year may involve full out-of-pocket exposure.

The Amgen Repatha Copay Card can reduce this to $0/month for eligible commercially insured patients, with a cap of up to $3,600 per year in savings per the program terms at time of publication. Medicare and Medicaid patients are not eligible for the manufacturer savings card per federal law [14]. Patients on Medicare Part D who meet income and asset thresholds may apply to Amgen's patient assistance program instead.

For patients whose plans route specialty drugs through a specialty pharmacy, the savings card typically works at Accredo, CVS Specialty, or Walgreens Specialty, all of which are in Anthem's preferred specialty pharmacy network for most regions.

How to Appeal a Repatha Denial from Anthem

Anthem denials for Repatha fall into two categories: a standard denial (PA not met) and a step-therapy denial (step requirements not fulfilled or documented). The appeal process follows the same general path for both [15].

Step 1: First-Level Internal Appeal. Submit within 180 days of the denial notice. Your prescriber's office should submit a written appeal with all documentation from the PA readiness checklist above, plus a point-by-point rebuttal of each denial reason listed in the explanation of benefits or denial letter. Reference specific guideline language: the 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction recommends evolocumab for patients with ASCVD who remain above LDL-C 70 mg/dL despite maximally tolerated oral therapy [16]. Cite that document by name.

Step 2: Second-Level Internal Appeal or Peer-to-Peer Review. If the first-level appeal fails, request a peer-to-peer review. This is a direct phone call between your cardiologist or lipidologist and Anthem's medical director. Peer-to-peer reviews reverse denials in a meaningful proportion of cases when conducted by a specialist who can address clinical specifics in real time. Request this within 30 days of the first denial.

Step 3: External Independent Review Organization (IRO). If the internal appeal fails, every state requires insurers to offer access to an external IRO, an independent body of clinicians not employed by Anthem that reviews the case de novo. For urgent or expedited situations, IRO decisions can come within 72 hours. IRO reversal rates for specialty cardiovascular drugs vary by state but average approximately 40% to 60% in favor of the patient in published analyses of external review outcomes [17].

Step 4: State Insurance Commissioner. If the IRO upholds the denial, you may file a complaint with your state's insurance commissioner. This step does not guarantee coverage but creates a formal regulatory record and occasionally prompts the insurer to reconsider.

Dr. Vera Bittner, former president of the American Heart Association's Council on Clinical Cardiology, has noted in published commentary that "failure to treat patients with established ASCVD to guideline-recommended LDL targets represents a preventable burden of recurrent events," a statement that directly supports the clinical necessity argument in Repatha appeals [18].

Special Situations: Anthem Medicaid, Medicare Advantage, and Federal Employee Plans

Anthem administers Medicaid managed care plans in several states under the Elevance Health name. Medicaid coverage for Repatha varies by state Medicaid formulary and is separate from commercial plan policy. Some state Medicaid programs cover evolocumab with PA for ASCVD and FH indications; others restrict coverage to HoFH only or require additional specialist confirmation [19].

Anthem Medicare Advantage plans follow CMS coverage rules as a floor but may apply additional PA requirements. Medicare Part D does not count toward the Amgen savings card eligibility, so cost-sharing for Medicare Advantage patients depends entirely on the plan's specialty drug cost-sharing structure and whether the patient qualifies for the Low Income Subsidy (LIS/Extra Help program) [20].

Federal Employee Program (FEP) plans administered by Anthem follow OPM formulary guidelines, which may differ from standard commercial plans. FEP Blue typically covers Repatha with PA but may apply different step-therapy thresholds than commercial products.

What Anthem Looks for in a Letter of Medical Necessity

A letter of medical necessity (LMN) is the single most important document in a Repatha PA submission. A weak LMN is the most common correctable reason for denial [21].

An effective LMN for evolocumab includes: the patient's specific diagnosis with ICD-10 code; LDL-C history over time with dates and values; a list of all lipid-lowering therapies tried, with doses and dates; objective documentation of any adverse effects; the clinician's clinical reasoning linking evolocumab to the reduction of specific cardiovascular events; and a direct citation to an applicable guideline or clinical trial.

The FOURIER trial showed that each 39 mg/dL reduction in LDL-C with evolocumab was associated with a 24% reduction in major adverse cardiovascular events over the treatment period [2]. Citing this figure with the NEJM reference number in the LMN connects the prescription directly to evidence-based medicine, which Anthem's medical reviewers cannot easily dismiss.

The ACC/AHA Pocket Guide on Cholesterol Management recommends that for very-high-risk patients with ASCVD, if LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe, "it is reasonable to add a PCSK9 inhibitor" [6]. That language, "reasonable to add," is guideline Class IIa evidence. Quoting it directly in the LMN anchors the request in standard of care.

Biosimilar Considerations for Evolocumab in 2025

As of mid-2025, no FDA-approved biosimilar to evolocumab has entered the U.S. market, though biosimilar applications are under review. If a biosimilar reaches commercial availability, Anthem plans are likely to add it to formulary at a preferred specialty tier and apply step therapy requiring the biosimilar before the reference product [22].

Patients already stable on branded Repatha may be subject to formulary exceptions if biosimilars are listed at a preferred tier. Monitor your plan's annual formulary update each fall, typically released in October for the following plan year.

The other approved PCSK9 inhibitor, alirocumab (Praluent, Sanofi/Regeneron), is on some Anthem formularies as a preferred alternative to evolocumab. If your plan prefers alirocumab and your prescriber has no specific clinical reason to require evolocumab, switching to alirocumab 75 mg or 150 mg every two weeks may resolve a coverage dispute faster than a prolonged appeal [23].

When to Involve a Pharmacist or Patient Advocate

Hospital-based clinical pharmacists and independent patient advocates who specialize in specialty drug access can materially change PA and appeal outcomes. They know the specific language Anthem's reviewers respond to, the exact documentation format each PBM platform requires, and the timelines for escalation.

Amgen's own reimbursement support line (1-844-REPATHA) connects patients with case managers who can help coordinate PA submissions and appeals at no cost to the patient. This service is separate from the savings card program and available regardless of income [24].

If your prescriber is in a large cardiology or health system practice, a specialty pharmacy liaison or prior authorization coordinator on staff can handle the paperwork while the physician focuses on clinical management. Practices without dedicated PA staff have significantly higher denial rates on first submission.

LDL-C of 70 mg/dL is the evidence-based threshold for adding a PCSK9 inhibitor in very-high-risk ASCVD patients on maximally tolerated oral therapy. If your most recent lab result shows LDL-C above that number on documented high-intensity statin plus ezetimibe, you meet the clinical threshold and your prescriber has a clear, guideline-supported reason to write the PA today [6].